He will replace Davinder Gill who will leave as CEO of the company on January 31, 2020, Hilleman Laboratories said in a statement.
Rao has more than 22 years' experience in research and development, manufacturing and commercialisation of vaccines for infectious diseases, and is joining from Takeda Vaccines where he was Vice President of Global Product Operations, it added.
Established in 2009, Hilleman Laboratories is a research and development joint venture with a not-for-profit mission to develop affordable vaccines for diseases that commonly affect low-income countries. AKT AKT ANS ANS